General synthesis of α-substituted 3-bisaryloxy propionic acid derivatives as specific MMP inhibitors

被引：17

作者：

Chollet, AM

Le Diguarher, T

Murray, L

Bertrand, M

Tucker, GC

Sabatini, M

Pierré, A

Atassi, G

Bonnet, J

Casara, P

机构：

[1] Inst Rech Servier, F-78290 Croissy Sur Seine, France

[2] Inst Rech Servier, F-92150 Suresnes, France

[3] Technol Servier, F-45007 Orleans, France

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2001年 / 11卷 / 03期

关键词：

D O I：

10.1016/S0960-894X(00)00646-6

中图分类号：

R914 [药物化学];

学科分类号：

100701 [药物化学];

摘要：

Modulations of alpha and aryl substitutions on 3-aryloxy propionic acid hydroxamates led to novel and potent inhibitors of MMP-2.3,9 and 13, and selectivity versus MMP-1. (C) 2001 Elsevier Science Ltd. All rights reserved.

引用

页码：295 / 299

页数：5

共 42 条

[1]

Aoudjit F, 1998, J IMMUNOL, V160, P2967

[2]

Matrix metalloproteinase inhibitors 1998 [J].

Beckett, RP ;

Whittaker, M .

EXPERT OPINION ON THERAPEUTIC PATENTS, 1998, 8 (03) :259-282

[3]

Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage [J].

Billinghurst, RC ;

Dahlberg, L ;

Ionescu, M ;

Reiner, A ;

Bourne, R ;

Rorabeck, C ;

Mitchell, P ;

Hambor, J ;

Diekmann, O ;

Tschesche, H ;

Chen, J ;

VanWart, H ;

Poole, AR .

JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1534-1545

[4]

MATRIX METALLOPROTEINASES - A REVIEW [J].

BIRKEDALHANSEN, H ;

MOORE, WGI ;

BODDEN, MK ;

WINDSOR, LJ ;

BIRKEDALHANSEN, B ;

DECARLO, A ;

ENGLER, JA .

CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 1993, 4 (02) :197-250

[5]

Cytokine control of interstitial collagenase and collagenase-3 gene expression in human chondrocytes [J].

Borden, P ;

Solymar, D ;

Sucharczuk, A ;

Lindman, B ;

Cannon, P ;

Heller, RA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (38) :23577-23581

[6]

Matrix metalloproteinase inhibitors in arthritis [J].

Bottomley, KM ;

Johnson, WH ;

Walter, DS .

JOURNAL OF ENZYME INHIBITION, 1998, 13 (02) :79-101

[7]

Design and synthesis of the cartilage protective agent (CPA, Ro32-3555) [J].

Broadhurst, MJ ;

Brown, PA ;

Lawton, G ;

Ballantyne, N ;

Borkakoti, N ;

Bottomley, KMK ;

Cooper, MI ;

Eatherton, AJ ;

Kilford, IR ;

Malsher, PJ ;

Nixon, JS ;

Lewis, EJ ;

Sutton, BM ;

Johnson, WH .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (17) :2299-2302

[8]

BROADHURST MJ, 1997, J MED CHEM, V40, P2525

[9]

MATRIX METALLOPROTEINASE INHIBITORS CONTAINING A (CARBOXYALKYL)AMINO ZINC LIGAND - MODIFICATION OF THE P1 AND P2' RESIDUES [J].

BROWN, FK ;

BROWN, PJ ;

BICKETT, DM ;

CHAMBERS, CL ;

DAVIES, HG ;

DEATON, DN ;

DREWRY, D ;

FOLEY, M ;

MCELROY, AB ;

GREGSON, M ;

MCGEEHAN, GM ;

MYERS, PL ;

NORTON, D ;

SALOVICH, JM ;

SCHOENEN, FJ ;

WARD, P .

JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (05) :674-688

[10]

Clinical studies with matrix metalloproteinase inhibitors [J].

Brown, PD .

APMIS, 1999, 107 (01) :174-180

← 1 2 3 4 5 →